The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

What is new in targeted therapies for AML?

During the 2nd National Cancer Research Institute (NCRI) AML Academy meeting, which took place on October 8–9, 2020, we spoke to Executive Steering Committee Member Navel Daver, MD Anderson Cancer Center, Houston, US, about new targeted therapies in AML.

What is new in targeted therapies for AML?

In this video, Navel Daver discusses the use of single agents, such as the FLT3 inhibitor, gilteritinib, and the IDH1 inhibitor, ivosidenib, as well as the outcomes of more recent combination treatments with venetoclax in doublet and triplet therapies.

Share: